Metformin Therapy Guidelines

Introduction to Metformin Therapy

• Metformin commonly causes gastrointestinal side effects and rarely can lead to serious complications such as lactic acidosis, particularly in patients with renal insufficiency, requiring careful monitoring and appropriate patient selection 1

Risk Factors and Contraindications

• The American Diabetes Association recommends that metformin is contraindicated in patients with eGFR <30 mL/min/1.73 m², hypoperfusion or hypoxemia, impaired hepatic function, heart failure, alcohol abuse, acute illness with dehydration, and use of iodinated contrast agents 1
• Patients with advanced renal insufficiency (eGFR <30 mL/min/1.73 m²) should not use metformin due to the increased risk of lactic acidosis 1

Dosing and Administration

• Gradual dose titration, starting with low doses and gradually increasing, can minimize GI side effects 1
• Dose reduction or discontinuation should be considered if GI side effects persist despite mitigation strategies 1

Monitoring and Management

• Regular monitoring of renal function is recommended every 3-6 months in at-risk patients 1
• Temporary discontinuation of metformin is recommended during procedures using iodinated contrast, hospitalizations, and acute illness that may compromise renal or liver function 1
• Monitoring of vitamin B12 levels is recommended for patients on long-term metformin therapy due to the increased risk of vitamin B12 deficiency 1, 2

Special Considerations

• Patients with eGFR ≥30 mL/min/1.73 m² can safely use metformin, while those with eGFR 30-45 mL/min/1.73 m² should use lower doses with careful monitoring 1
• Excessive alcohol intake increases the risk of lactic acidosis, and patients should be advised against binge drinking or regular heavy alcohol consumption 1